Q32 Bio Inc. QTTB

NAS: QTTB | ISIN: US7469641051 8/07/2025

1,390 USD (+2,21%)

(+2,21%) 8/07/2025

Toon enkel gratis nieuws

8 mei 2025 · Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update · Persbericht

30 april 2025 · Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata · Persbericht

16 april 2025 · Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata · Persbericht

11 maart 2025 · Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

8 maart 2025 · Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting · Persbericht

29 augustus 2024 · Q32 Bio to Participate in Upcoming September Investor Conferences · Persbericht

9 juli 2024 · Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis · Persbericht

1 juli 2024 · Q32 Bio Joins Russell 3000® Index · Persbericht

9 mei 2024 · Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

3 april 2024 · Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe